TARACTAN
LOE ApproachingNDAORALCONCENTRATE
Approved
Jun 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARACTAN is an oral concentrate small-molecule drug approved by Roche in 1967 for an unknown indication. The mechanism of action and pharmacologic class are not specified in available data.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial teams are likely in maintenance mode with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TARACTAN currently shows zero linked job openings, reflecting its late-lifecycle status and minimal commercial activity. Career opportunities on this asset are limited to legacy support, compliance, and patient access roles.
Brand ManagerField Sales Representative
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.